First Time Loading...

Medley Inc
TSE:4480

Watchlist Manager
Medley Inc Logo
Medley Inc
TSE:4480
Watchlist
Price: 3 695 JPY -0.4% Market Closed
Updated: Apr 29, 2024
Section:
 

Relative Value

The Relative Value of one Medley Inc stock under the Base Case scenario is 3 020.73 JPY. Compared to the current market price of 3 695 JPY, Medley Inc is Overvalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
3 020.73 JPY
Overvaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.8
P/S
P/S
Price to Sales
5.8
vs History
85
vs Industry
23
Median 3Y
8.5
Median 5Y
8.7
Industry
2.4
Forward
4.3
More Details
46.6
P/E
P/E
Price to Earnings
46.6
vs History
79
vs Industry
10
Median 3Y
111.2
Median 5Y
104.1
Industry
23.2
Forward
42.5
More Details
30.9
P/OCF
P/OCF
Price to OCF
30.9
vs History
62
vs Industry
12
Median 3Y
62.7
Median 5Y
46.1
Industry
15.5
More Details
54.7
P/FCFE
P/FCFE
Price to FCFE
54.7
vs History
42
vs Industry
11
Median 3Y
65.2
Median 5Y
42.2
Industry
23.5
More Details
6.8
P/B
P/B
Price to Book Value
6.8
vs History
77
vs Industry
11
Median 3Y
8.3
Median 5Y
8.9
Industry
2.2
More Details
5.1
EV/S
EV/S
Enterprise Value to Sales
5.1
vs History
81
vs Industry
23
Median 3Y
7.4
Median 5Y
7.5
Industry
2.5
Forward
3.8
More Details
7.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.7
vs History
81
vs Industry
29
Median 3Y
11.1
Median 5Y
11.3
Industry
5.2
More Details
31.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
31.7
vs History
85
vs Industry
9
Median 3Y
54.2
Median 5Y
55.3
Industry
12.5
Forward
21.7
More Details
39.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
39.5
vs History
85
vs Industry
10
Median 3Y
78.9
Median 5Y
81.1
Industry
17.2
More Details
27.2
EV/OCF
EV/OCF
Enterprise Value to OCF
27.2
vs History
62
vs Industry
16
Median 3Y
56.2
Median 5Y
42
Industry
15.1
More Details
30.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
30.3
vs History
62
vs Industry
18
Median 3Y
69.3
Median 5Y
47.4
Industry
19.7
More Details
10.8
EV/IC
EV/IC
Enterprise Value to IC
10.8
vs History
92
vs Industry
7
Median 3Y
15.3
Median 5Y
18.9
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
Medley Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Medley Inc
TSE:4480
119.5B JPY 5.8 46.6 31.7 39.5
US
Veeva Systems Inc
NYSE:VEEV
32.4B USD 13.7 61.6 61.4 66.1
US
Cerner Corp
NASDAQ:CERN
27.9B USD 4.8 47.3 19.6 38.6
US
Change Healthcare Inc
NASDAQ:CHNG
9B USD 2.6 -116.8 16.5 111.6
JP
M3 Inc
TSE:2413
1.3T JPY 5.4 27.5 14.6 16.4
AU
Pro Medicus Ltd
ASX:PME
11.4B AUD 78.1 163.9 112.7 112.7
US
Inspire Medical Systems Inc
NYSE:INSP
7B USD 11.2 -331.8 -175.3 -162.9
US
Doximity Inc
NYSE:DOCS
4.4B USD 9.5 32.2 21.5 22.9
SE
Sectra AB
STO:SECT B
42.7B SEK 26.1 100.6 -66.2 -66.2
US
Evolent Health Inc
NYSE:EVH
3.1B USD 1.6 -22.1 26.1 277.7
US
Goodrx Holdings Inc
NASDAQ:GDRX
2.8B USD 3.8 -319.5 34.1 -111.3
P/E Multiple
Earnings Growth
JP
Medley Inc
TSE:4480
Average P/E: 68.5
46.6
126%
US
Veeva Systems Inc
NYSE:VEEV
61.6
139%
US
Cerner Corp
NASDAQ:CERN
47.3
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
Negative Multiple: -116.8 N/A
JP
M3 Inc
TSE:2413
27.5
26%
AU
Pro Medicus Ltd
ASX:PME
163.9
119%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -331.8 N/A
US
Doximity Inc
NYSE:DOCS
32.2
79%
SE
Sectra AB
STO:SECT B
100.6
56%
US
Evolent Health Inc
NYSE:EVH
Negative Multiple: -22.1 N/A
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -319.5 N/A
EV/EBITDA Multiple
EBITDA Growth
JP
Medley Inc
TSE:4480
Average EV/EBITDA: 37.6
31.7
174%
US
Veeva Systems Inc
NYSE:VEEV
61.4
221%
US
Cerner Corp
NASDAQ:CERN
19.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
16.5
N/A
JP
M3 Inc
TSE:2413
14.6
24%
AU
Pro Medicus Ltd
ASX:PME
112.7
124%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -175.3 N/A
US
Doximity Inc
NYSE:DOCS
21.5
103%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.2 N/A
US
Evolent Health Inc
NYSE:EVH
26.1
194%
US
Goodrx Holdings Inc
NASDAQ:GDRX
34.1
305%
EV/EBIT Multiple
EBIT Growth
JP
Medley Inc
TSE:4480
Average EV/EBIT: 85.7
39.5
N/A
US
Veeva Systems Inc
NYSE:VEEV
66.1
238%
US
Cerner Corp
NASDAQ:CERN
38.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
111.6
N/A
JP
M3 Inc
TSE:2413
16.4
N/A
AU
Pro Medicus Ltd
ASX:PME
112.7
110%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -162.9 N/A
US
Doximity Inc
NYSE:DOCS
22.9
116%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.2 N/A
US
Evolent Health Inc
NYSE:EVH
277.7
2 086%
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -111.3 N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.